

Martin Stangel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8380206/publications.pdf>

Version: 2024-02-01

270
papers

12,030
citations

28736

57
h-index

42259

96
g-index

288
all docs

288
docs citations

288
times ranked

14156
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
2	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	2.8	17
3	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. <i>Neurological Research and Practice</i> , 2022, 4, 1.	1.0	9
4	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.5	14
5	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. <i>Journal of Neuroinflammation</i> , 2022, 19, 19.	3.1	82
6	The Influence of the Ventricular-Lumbar Gradient on Cerebrospinal Fluid Analysis in Serial Samples. <i>Brain Sciences</i> , 2022, 12, 410.	1.1	4
7	Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination. <i>Histochemistry and Cell Biology</i> , 2022, 158, 15-38.	0.8	12
8	Cuprizone-induced demyelination triggers a $CD8^+$ pronounced T cell recruitment. <i>Glia</i> , 2021, 69, 925-942.	2.5	24
9	The influence of the CRS-R score on functional outcome in patients with severe brain injury receiving early rehabilitation. <i>BMC Neurology</i> , 2021, 21, 44.	0.8	13
10	Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients. <i>Brain Sciences</i> , 2021, 11, 296.	1.1	12
11	Auditory Stimulation Modulates Resting-State Functional Connectivity in Unresponsive Wakefulness Syndrome Patients. <i>Frontiers in Neuroscience</i> , 2021, 15, 554194.	1.4	7
12	CIDP associated with Sjögren's syndrome. <i>Journal of Neurology</i> , 2021, 268, 2908-2912.	1.8	15
13	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin's lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 127-134.	0.5	1
14	Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System. <i>Frontiers in Digital Health</i> , 2021, 3, 633427.	1.5	5
15	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 8527.	1.6	6
16	Rare germline variants in the E-cadherin gene CDH1 are associated with the risk of brain tumors of neuroepithelial and epithelial origin. <i>Acta Neuropathologica</i> , 2021, 142, 191-210.	3.9	6
17	Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devices—A Critical Appraisal. <i>Cells</i> , 2021, 10, 1232.	1.8	8
18	Elevated Free Phosphatidylcholine Levels in Cerebrospinal Fluid Distinguish Bacterial from Viral CNS Infections. <i>Cells</i> , 2021, 10, 1115.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1020.	3.1	19
20	Active Case Finding of Current Bornavirus Infections in Human Encephalitis Cases of Unknown Etiology, Germany, 2018â€“2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 1371-1379.	2.0	38
21	MyD88 signaling by neurons induces chemokines that recruit protective leukocytes to the virus-infected CNS. <i>Science Immunology</i> , 2021, 6, .	5.6	12
22	Sequential MAVS and MyD88/TRIF signaling triggers antiâ€viral responses of tickâ€borne encephalitis virusâ€infected murine astrocytes. <i>Journal of Neuroscience Research</i> , 2021, 99, 2478-2492.	1.3	6
23	Nerve ultrasound findings in SjÃ¶rgren's syndromeâ€associated neuropathy. <i>Journal of Neuroimaging</i> , 2021, 31, 1156-1165.	1.0	5
24	Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	18
25	Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets â€ expert opinion on issues in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103075.	0.9	3
26	Treatment of upper limb spasticity with inhibitory repetitive transcranial magnetic stimulation: A randomized placebo-controlled trial. <i>NeuroRehabilitation</i> , 2021, 49, 425-434.	0.5	14
27	Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110091.	1.5	1
28	PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199368.	1.5	9
29	Introduction and spread of variegated squirrel bornavirus 1 (VSBV-1) between exotic squirrels and spill-over infections to humans in Germany. <i>Emerging Microbes and Infections</i> , 2021, 10, 602-611.	3.0	14
30	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	38
31	Evidence of Oligoclonal Bands Does Not Exclude Non-Inflammatory Neurological Diseases. <i>Diagnostics</i> , 2021, 11, 37.	1.3	19
32	Toll-like Receptors in Viral Encephalitis. <i>Viruses</i> , 2021, 13, 2065.	1.5	10
33	Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2228-2234.	1.7	4
34	Regenerative Effects of CDP-Choline: A Dose-Dependent Study in the Toxic Cuprizone Model of De- and Remyelination. <i>Pharmaceutics</i> , 2021, 14, 1156.	1.7	4
35	Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. <i>Lancet Neurology</i> , The, 2021, 20, 991-1000.	4.9	16
36	The Influence of Renal Function Impairment on Kappa Free Light Chains in Cerebrospinal Fluid. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110421.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Standardized nutritional supply versus individual nutritional assessment: Impact on weight changes, complications and functional outcome from neurological early rehabilitation. <i>Clinical Nutrition</i> , 2020, 39, 1225-1233.	2.3	1
38	Phosphatidylcholine PC ae C44:6 in cerebrospinal fluid is a sensitive biomarker for bacterial meningitis. <i>Journal of Translational Medicine</i> , 2020, 18, 9.	1.8	12
39	The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101863.	0.9	22
40	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <sc>PATH</sc> study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 230-237.	1.4	15
41	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e827.	3.1	7
42	Cognitive impairment in patients with Neuroâ€šjÃ¶gren. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1352-1359.	1.7	14
43	Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 65.	2.4	5
44	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
45	Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. <i>Journal of Clinical Medicine</i> , 2020, 9, 4067.	1.0	53
46	Hearing dysfunction in patients with Neuro-SjÃ¶gren: a cross-sectional study. <i>Annals of Translational Medicine</i> , 2020, 8, 1069-1069.	0.7	9
47	Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis. <i>Frontiers in Neurology</i> , 2020, 11, 602102.	1.1	28
48	Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. <i>PLoS ONE</i> , 2020, 15, e0231846.	1.1	16
49	Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patientsâ€™ Lessons Learned From SARS and MERS. <i>Frontiers in Immunology</i> , 2020, 11, 1059.	2.2	20
50	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	0.9	66
51	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	2.7	67
52	Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e654.	3.1	26
53	Is APOE Î¼4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e728.	3.1	11
54	Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse. <i>Journal of Neurology</i> , 2020, 267, 2803-2805.	1.8	20

#	ARTICLE	IF	CITATIONS
55	Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 583-594.	1.9	13
56	Delayed Demyelination and Impaired Remyelination in Aged Mice in the Cuprizone Model. <i>Cells</i> , 2020, 9, 945.	1.8	26
57	FoxP3 deficiency causes no inflammation or neurodegeneration in the murine brain. <i>Journal of Neuroimmunology</i> , 2020, 342, 577216.	1.1	3
58	The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. <i>Cells</i> , 2020, 9, 842.	1.8	25
59	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , 2020, 161, 787-796.	2.0	29
60	Targeted metabolomic profiling of cerebrospinal fluid from patients with progressive multifocal leukoencephalopathy. <i>PLoS ONE</i> , 2020, 15, e0242321.	1.1	2
61	The Influence of Blood Contamination on Cerebrospinal Fluid Diagnostics. <i>Frontiers in Neurology</i> , 2019, 10, 584.	1.1	24
62	Immunity in Gilles de la Tourette-Syndrome: Results From a Cerebrospinal Fluid Study. <i>Frontiers in Neurology</i> , 2019, 10, 732.	1.1	17
63	Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 1600.	2.2	64
64	Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen. <i>Frontiers in Neurology</i> , 2019, 10, 735.	1.1	14
65	Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis Under Immunosuppression After Liver Transplantation. <i>Frontiers in Neurology</i> , 2019, 10, 987.	1.1	12
66	Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia. <i>Journal of Translational Medicine</i> , 2019, 17, 365.	1.8	38
67	Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics. <i>Frontiers in Neurology</i> , 2019, 10, 839.	1.1	38
68	Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 28.	2.4	3
69	Fumaric Acids Do Not Directly Influence Gene Expression of Neuroprotective Factors in Highly Purified Rodent Astrocytes. <i>Brain Sciences</i> , 2019, 9, 241.	1.1	5
70	Investigation of Neuregulin-1 and Glial Cell-Derived Neurotrophic Factor in Rodent Astrocytes and Microglia. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 484-493.	1.1	11
71	Polarized microglia do not influence oligodendrocyte lineage cells via astrocytes. <i>International Journal of Developmental Neuroscience</i> , 2019, 77, 39-47.	0.7	5
72	Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and Viral Central Nervous System Infections. <i>Journal of Infectious Diseases</i> , 2019, 220, 127-138.	1.9	37

#	ARTICLE	IF	CITATIONS
73	Fumaric Acids Directly Influence Gene Expression of Neuroprotective Factors in Rodent Microglia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 325.	1.8	22
74	Identification of Cerebrospinal Fluid Metabolites as Biomarkers for Enterovirus Meningitis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 337.	1.8	14
75	Investigation of Oligoclonal IgG Bands in Tear Fluid of Multiple Sclerosis Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1110.	2.2	16
76	Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient. <i>Frontiers in Immunology</i> , 2019, 10, 1188.	2.2	11
77	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. <i>Annals of Hematology</i> , 2019, 98, 1905-1918.	0.8	61
78	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	4.5	48
79	Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 188.	1.1	52
80	Reiber's Diagram for Kappa Free Light Chains: The New Standard for Assessing Intrathecal Synthesis?. <i>Diagnostics</i> , 2019, 9, 194.	1.3	24
81	HSV-1 triggers paracrine fibroblast growth factor response from cortical brain cells via immediate-early protein ICPO. <i>Journal of Neuroinflammation</i> , 2019, 16, 248.	3.1	16
82	Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641988759.	1.5	13
83	Acute progressive neuropathy's myositis's myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 435-440.	0.6	23
84	Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients. <i>Cells</i> , 2019, 8, 12.	1.8	109
85	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	1.8	24
86	Intravenous versus subcutaneous immunoglobulin - Authors' reply. <i>Lancet Neurology</i> , The, 2018, 17, 393-394.	4.9	0
87	Cerebrospinal fluid features in adults with enteroviral nervous system infection. <i>International Journal of Infectious Diseases</i> , 2018, 68, 94-101.	1.5	21
88	Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 87-89.	0.9	2
89	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e446.	3.1	54
90	Management of MS-relapse during alemtuzumab therapy: Is it really B-cell-mediated?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 6-7.	0.9	2

#	ARTICLE	IF	CITATIONS
91	Paraneoplastic cerebellar syndromes associated with antibodies against Purkinje cells. <i>International Journal of Neuroscience</i> , 2018, 128, 721-728.	0.8	9
92	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	4.9	193
93	The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3796.	1.8	34
94	Type I Interferon Receptor Signaling of Neurons and Astrocytes Regulates Microglia Activation during Viral Encephalitis. <i>Cell Reports</i> , 2018, 25, 118-129.e4.	2.9	84
95	IFN- γ Producing Th1 Cells Induce Different Transcriptional Profiles in Microglia and Astrocytes. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 352.	1.8	28
96	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	3.1	173
97	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
98	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. <i>Lancet Neurology</i> , The, 2018, 17, 498.	4.9	17
99	Mesenchymal Stem Cells Form 3D Clusters Following Intraventricular Transplantation. <i>Journal of Molecular Neuroscience</i> , 2018, 65, 60-73.	1.1	17
100	Chronic Granulomatous Disease First Diagnosed in Adulthood Presenting With Spinal Cord Infection. <i>Frontiers in Immunology</i> , 2018, 9, 1258.	2.2	7
101	Beneficial and detrimental impact of transplanted canine adipose-derived stem cells in a virus-induced demyelinating mouse model. <i>Veterinary Immunology and Immunopathology</i> , 2018, 202, 130-140.	0.5	3
102	Varicella zoster virus infections in neurological patients: a clinical study. <i>BMC Infectious Diseases</i> , 2018, 18, 238.	1.3	41
103	Immunophenotyping of cerebrospinal fluid cells by Chipcytometry. <i>Journal of Neuroinflammation</i> , 2018, 15, 160.	3.1	13
104	Mass-spectrometric profiling of cerebrospinal fluid reveals metabolite biomarkers for CNS involvement in varicella zoster virus reactivation. <i>Journal of Neuroinflammation</i> , 2018, 15, 20.	3.1	22
105	Impairment of frequency-specific responses associated with altered electrical activity patterns in auditory thalamus following focal and general demyelination. <i>Experimental Neurology</i> , 2018, 309, 54-66.	2.0	15
106	Regulation of neuroinflammatory properties of glial cells by T cell effector molecules. <i>Neural Regeneration Research</i> , 2018, 13, 234.	1.6	9
107	The Effect of Stereotactic Injections on Demyelination and Remyelination: a Study in the Cuprizone Model. <i>Journal of Molecular Neuroscience</i> , 2017, 61, 479-488.	1.1	21
108	Investigation of Cuprizone Inactivation by Temperature. <i>Neurotoxicity Research</i> , 2017, 31, 570-577.	1.3	6

#	ARTICLE	IF	CITATIONS
109	Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization. <i>BMC Infectious Diseases</i> , 2017, 17, 90.	1.3	71
110	Gain-of-function STAT1 mutations are associated with intracranial aneurysms. <i>Clinical Immunology</i> , 2017, 178, 79-85.	1.4	19
111	Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. <i>European Journal of Haematology</i> , 2017, 99, 169-177.	1.1	29
112	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	0.9	123
113	Cerebrospinal Fluid Findings in Neurological Diseases Associated with Sjögren's Syndrome. <i>European Neurology</i> , 2017, 77, 91-102.	0.6	27
114	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	4.9	472
115	Polysialylation at Early Stages of Oligodendrocyte Differentiation Promotes Myelin Repair. <i>Journal of Neuroscience</i> , 2017, 37, 8131-8141.	1.7	26
116	Autoantibodies binding to stathmin-4: new marker for polyneuropathy in primary Sjögren's syndrome. <i>Immunologic Research</i> , 2017, 65, 1099-1102.	1.3	8
117	Synaptophysin Is a Reliable Marker for Axonal Damage. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 109-125.	0.9	61
118	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	1.4	60
119	The quality of cortical network function recovery depends on localization and degree of axonal demyelination. <i>Brain, Behavior, and Immunity</i> , 2017, 59, 103-117.	2.0	25
120	Achievements and obstacles of remyelinating therapies in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2017, 13, 742-754.	4.9	89
121	Clinically Isolated Syndrome According to McDonald 2010: Intrathecal IgG Synthesis Still Predictive for Conversion to Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2061.	1.8	23
122	Weaning of neurological early rehabilitation patients from mechanical ventilation: a retrospective observational study. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2017, 53, 441-446.	1.1	6
123	Effectors of Th1 and Th17 cells act on astrocytes and augment their neuroinflammatory properties. <i>Journal of Neuroinflammation</i> , 2017, 14, 204.	3.1	88
124	Contribution of QSM Imaging to the Diagnosis of the Rare Syndrome of Leukoencephalopathy with Cysts and Calcification (LCC). <i>Clinical Neuroradiology</i> , 2017, 27, 477-479.	1.0	5
125	McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1592.	1.8	34
126	Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2106.	1.8	13

#	ARTICLE	IF	CITATIONS
127	Astrocytes Enhance Streptococcus suis-Glial Cell Interaction in Primary Astrocyte-Microglial Cell Co-Cultures. <i>Pathogens</i> , 2016, 5, 43.	1.2	7
128	In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia. <i>Journal of Neuroinflammation</i> , 2016, 13, 250.	3.1	36
129	Longitudinal time-domain optic coherence study of retinal nerve fiber layer in IFN β -treated and untreated multiple sclerosis patients. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 190-200.	0.8	9
130	Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 165-179.	1.5	14
131	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a Germanâ€‘Austrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	1.8	46
132	Intraspinal cavernous bleeding during early pregnancy. <i>Journal of Neurology</i> , 2016, 263, 2127-2129.	1.8	3
133	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. <i>BMC Neurology</i> , 2016, 16, 98.	0.8	15
134	Cytokine regulation by modulation of the NMDA receptor on astrocytes. <i>Neuroscience Letters</i> , 2016, 629, 227-233.	1.0	18
135	Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis. <i>BMC Neurology</i> , 2016, 16, 136.	0.8	24
136	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	4.7	133
137	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	2.8	315
138	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsingâ€‘remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1202-1214.	1.4	40
139	Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis. <i>Neural Regeneration Research</i> , 2016, 11, 90.	1.6	2
140	The antiviral drug ganciclovir does not inhibit microglial proliferation and activation. <i>Scientific Reports</i> , 2015, 5, 14935.	1.6	13
141	Effect of FTY720-phosphate on the expression of inflammation-associated molecules in astrocytes in vitro. <i>Molecular Medicine Reports</i> , 2015, 12, 6171-6177.	1.1	23
142	Acute hemorrhagic leukoencephalitis (Weston-Hurst syndrome) in a patient with relapse-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 175.	3.1	14
143	Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. <i>Molecular Brain</i> , 2015, 8, 62.	1.3	10
144	Polysialic acid on SynCAM 1 in NG2 cells and on neuropilinâ€‘2 in microglia is confined to intracellular pools that are rapidly depleted upon stimulation. <i>Glia</i> , 2015, 63, 1240-1255.	2.5	37

#	ARTICLE	IF	CITATIONS
145	Effect of interferon- β 1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients. <i>Clinical and Experimental Immunology</i> , 2015, 182, 162-172.	1.1	8
146	Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1283-1292.	0.8	18
147	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	0.6	15
148	CSF Levels of Angiopoietin-2 Do Not Differ between Patients with CSF Fluid Leakage Syndrome and Controls. <i>Disease Markers</i> , 2015, 2015, 1-9.	0.6	2
149	Reply: Beneficial effects of exogenous CDP-choline (citicoline) in EAE. <i>Brain</i> , 2015, 138, e389-e389.	3.7	1
150	Upon Intranasal Vesicular Stomatitis Virus Infection, Astrocytes in the Olfactory Bulb Are Important Interferon Beta Producers That Protect from Lethal Encephalitis. <i>Journal of Virology</i> , 2015, 89, 2731-2738.	1.5	64
151	CXCL10 Triggers Early Microglial Activation in the Cuprizone Model. <i>Journal of Immunology</i> , 2015, 194, 3400-3413.	0.4	115
152	Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 155-165.	2.0	25
153	Pivotal role of choline metabolites in remyelination. <i>Brain</i> , 2015, 138, 398-413.	3.7	80
154	Towards the implementation of "no evidence of disease activity"™ in multiple sclerosis treatment: the multiple sclerosis decision model. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 3-13.	1.5	145
155	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1036-1044.	1.4	78
156	Oligodendroglial markers in the cuprizone model of CNS de- and remyelination. <i>Histology and Histopathology</i> , 2015, 30, 1455-64.	0.5	10
157	The choline pathway as a strategy to promote central nervous system (CNS) remyelination. <i>Neural Regeneration Research</i> , 2015, 10, 1369.	1.6	12
158	Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 73.	1.8	293
159	Limited role of regulatory T cells during acute Theiler virus-induced encephalitis in resistant C57BL/6 mice. <i>Journal of Neuroinflammation</i> , 2014, 11, 180.	3.1	16
160	Importance of Follow-Up Cerebrospinal Fluid Analysis in Cryptococcal Meningoencephalitis. <i>Disease Markers</i> , 2014, 2014, 1-10.	0.6	29
161	3,4-Diaminopyridine (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 293-300.	0.5	4
162	Defining the New End Point for Multiple Sclerosis Treatment. <i>JAMA Neurology</i> , 2014, 71, 1056.	4.5	2

#	ARTICLE	IF	CITATIONS
163	Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 905.	4.5	54
164	Varicella Zoster Virus Meningitis in a Young Immunocompetent Adult without Rash: A Misleading Clinical Presentation. <i>Case Reports in Neurological Medicine</i> , 2014, 2014, 1-4.	0.3	17
165	Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab. <i>Journal of Neuroinflammation</i> , 2014, 11, 19.	3.1	19
166	Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2014, 76, 792-801.	2.8	82
167	Natalizumab to fingolimod—the washout whitewash. <i>Nature Reviews Neurology</i> , 2014, 10, 311-313.	4.9	7
168	A pivotal role of nonmuscle myosin II during microglial activation. <i>Experimental Neurology</i> , 2014, 261, 666-676.	2.0	15
169	CD19 as a molecular target in CNS autoimmunity. <i>Acta Neuropathologica</i> , 2014, 128, 177-190.	3.9	22
170	Nitric oxide/cyclic GMP signaling regulates motility of a microglial cell line and primary microglia in vitro. <i>Brain Research</i> , 2014, 1564, 9-21.	1.1	23
171	Long-term impact of neonatal inflammation on demyelination and remyelination in the central nervous system. <i>Glia</i> , 2014, 62, 1659-1670.	2.5	18
172	Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia. <i>Brain, Behavior, and Immunity</i> , 2014, 37, 248-259.	2.0	65
173	Management of secondary immunodeficiencies with immunoglobulins (IG) under clinical practice conditions. <i>Journal of Clinical Oncology</i> , 2014, 32, e17596-e17596.	0.8	0
174	Treatment of Neurological Autoimmune Diseases with Immunoglobulins: First Insights from the Prospective SIGNS Registry. <i>Journal of Clinical Immunology</i> , 2013, 33, 67-71.	2.0	8
175	The fumaric acid ester BG-12: a new option in MS therapy. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 951-958.	1.4	15
176	2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. <i>Clinical and Experimental Immunology</i> , 2013, 173, 288-297.	1.1	28
177	Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. <i>Brain</i> , 2013, 136, 147-167.	3.7	298
178	Effects of fumaric acid esters on blood-brain barrier tight junction proteins. <i>Neuroscience Letters</i> , 2013, 555, 165-170.	1.0	26
179	Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 355-362.	1.3	25
180	Cuprizone [Bis(Cyclohexylidenehydrazide)] is Selectively Toxic for Mature Oligodendrocytes. <i>Neurotoxicity Research</i> , 2013, 24, 244-250.	1.3	122

#	ARTICLE	IF	CITATIONS
181	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. <i>Nature Reviews Neurology</i> , 2013, 9, 267-276.	4.9	181
182	Bloodâ€cerebrospinal fluid barrier dysfunction in patients with neurological symptoms during the 2011 Northern German E. coli serotype O104:H4 outbreak. <i>Brain</i> , 2013, 136, e241-e241.	3.7	9
183	CDP-choline is not protective in the SOD1-G93A mouse model of ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 284-290.	1.1	5
184	Ovarectomy despite Negative Imaging in Anti-NMDA Receptor Encephalitis: Effective Even Late. <i>Case Reports in Neurological Medicine</i> , 2013, 2013, 1-3.	0.3	26
185	Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. <i>Muscle and Nerve</i> , 2013, 48, 838-839.	1.0	28
186	Quantification of Microglial Phagocytosis by a Flow Cytometer-Based Assay. <i>Methods in Molecular Biology</i> , 2013, 1041, 121-127.	0.4	23
187	Therapeutic Potential of Mesenchymal Stromal Cells and MSC Conditioned Medium in Amyotrophic Lateral Sclerosis (ALS) - In Vitro Evidence from Primary Motor Neuron Cultures, NSC-34 Cells, Astrocytes and Microglia. <i>PLoS ONE</i> , 2013, 8, e72926.	1.1	60
188	Effects of Murine and Human Bone Marrow-Derived Mesenchymal Stem Cells on Cuprizone Induced Demyelination. <i>PLoS ONE</i> , 2013, 8, e69795.	1.1	43
189	Immunoadsorption Therapy for Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. <i>Blood Purification</i> , 2012, 33, 1-6.	0.9	32
190	Nervous system involvement of connective tissue disease. <i>Current Opinion in Neurology</i> , 2012, 25, 306-315.	1.8	10
191	Neurodegeneration and Neuroprotection in Multiple Sclerosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 4471-4474.	0.9	11
192	Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 939-950.	2.1	25
193	Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2012, 7, e51867.	1.1	36
194	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	3.1	593
195	Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2012, 20, 289-296.	0.8	3
196	Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. <i>Clinical Immunology</i> , 2012, 142, 44-48.	1.4	140
197	Pathogenic and physiological autoantibodies in the central nervous system. <i>Immunological Reviews</i> , 2012, 248, 68-86.	2.8	36
198	Cuprizone inhibits demyelinating leukomyelitis by reducing immune responses without virus exacerbation in an infectious model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 244, 84-93.	1.1	29

#	ARTICLE	IF	CITATIONS
199	Characterisation of microglia during de- and remyelination: Can they create a repair promoting environment?. <i>Neurobiology of Disease</i> , 2012, 45, 519-528.	2.1	161
200	Antibody-based therapy in Alzheimer's disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 343-357.	1.4	56
201	Longitudinal extensive transverse myelitisâ€”it's not all neuromyelitis optica. <i>Nature Reviews Neurology</i> , 2011, 7, 688-698.	4.9	141
202	Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1592-1606.	2.0	25
203	B-cell lymphoma infiltration of cerebrospinal fluid with minimal symptoms and benign course. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 978-980.	0.8	1
204	Remyelination in Multiple Sclerosis. , 2011, , 193-223.		1
205	Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 341.	1.0	45
206	Matrix Metalloproteinases and Their Tissue Inhibitors in Cuprizone-Induced Demyelination and Remyelination of Brain White and Gray Matter. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 758-769.	0.9	40
207	CCL5 induces a pro-inflammatory profile in microglia in vitro. <i>Cellular Immunology</i> , 2011, 270, 164-171.	1.4	92
208	Glatiramer Acetate Modulates TNF- α and IL-10 Secretion in Microglia and Promotes Their Phagocytic Activity. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 381-388.	2.1	53
209	Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. <i>Annals of Neurology</i> , 2011, 70, 520-520.	2.8	53
210	Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 123-134.	1.5	69
211	Spatial and Temporal Profiles of Growth Factor Expression during CNS Demyelination Reveal the Dynamics of Repair Priming. <i>PLoS ONE</i> , 2011, 6, e22623.	1.1	80
212	De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. <i>Histology and Histopathology</i> , 2011, 26, 1585-97.	0.5	169
213	Meningeal carcinomatosis from penile squamous cell carcinoma. <i>Journal of Neuro-Oncology</i> , 2010, 98, 417-419.	1.4	4
214	Beneficial Effects of Minocycline on Cuprizone Induced Cortical Demyelination. <i>Neurochemical Research</i> , 2010, 35, 1422-1433.	1.6	52
215	Autoantibodies against aquaporinâ€”4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2010, 62, 1198-1200.	6.7	88
216	Cerebellar Cortical Demyelination in the Murine Cuprizone Model. <i>Brain Pathology</i> , 2010, 20, 301-312.	2.1	86

#	ARTICLE	IF	CITATIONS
217	Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse. PLoS ONE, 2010, 5, e11769.	1.1	71
218	Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis. Current Medicinal Chemistry, 2010, 17, 640-650.	1.2	8
219	Interferon-beta treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation. Neuroscience Letters, 2010, 485, 107-111.	1.0	6
220	Remyelination after cuprizone induced demyelination is accelerated in mice deficient in the polysialic acid synthesizing enzyme St8sialIV. Neuroscience, 2010, 171, 235-244.	1.1	33
221	Hematopoietic stem cell transplantation: hope and hype. Nature Reviews Neurology, 2009, 5, 300-302.	4.9	6
222	Plasma Exchange Therapy in Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. Blood Purification, 2009, 28, 108-115.	0.9	69
223	Regional differences between grey and white matter in cuprizone induced demyelination. Brain Research, 2009, 1283, 127-138.	1.1	199
224	Demyelination of the hippocampus is prominent in the cuprizone model. Neuroscience Letters, 2009, 451, 83-88.	1.0	118
225	Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neuroscience Letters, 2009, 453, 120-125.	1.0	108
226	Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. Journal of the Neurological Sciences, 2009, 287, 257-259.	0.3	61
227	Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathology and Applied Neurobiology, 2008, 34, 105-114.	1.8	134
228	Neuroprotection and neuroregeneration in multiple sclerosis. Journal of Neurology, 2008, 255, 77-81.	1.8	43
229	The chemokine receptor CXCR2 is differentially regulated on glial cells <i>in vivo</i> but is not required for successful remyelination after cuprizone-induced demyelination. Glia, 2008, 56, 1104-1113.	2.5	37
230	Effects of interferon- β on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon- β treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 166-176.	1.4	45
231	Epileptic seizures and hippocampal damage after cuprizone-induced demyelination in C57BL/6 mice. Experimental Neurology, 2008, 210, 308-321.	2.0	94
232	Cortical Demyelination Is Prominent in the Murine Cuprizone Model and Is Strain-Dependent. American Journal of Pathology, 2008, 172, 1053-1061.	1.9	247
233	Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Therapeutic Advances in Neurological Disorders, 2008, 1, 115-124.	1.5	5
234	Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Review of Neurotherapeutics, 2008, 8, 1683-1690.	1.4	27

#	ARTICLE	IF	CITATIONS
235	Using immunoglobulins in muscular disease treatment. Expert Opinion on Biological Therapy, 2008, 8, 1143-1150.	1.4	5
236	A β -Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2008, 3, e3149.	1.1	76
237	Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. Nature Clinical Practice Neurology, 2007, 3, 36-44.	2.7	121
238	Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination. Acta Neuropathologica, 2007, 114, 587-596.	3.9	32
239	Modulation of rat oligodendrocyte precursor cells by the chemokine CXCL12. NeuroReport, 2006, 17, 1187-1190.	0.6	55
240	Current issues in immunomodulatory treatment of multiple sclerosis. Journal of Neurology, 2006, 253, i32-i36.	1.8	10
241	Basic principles of intravenous immunoglobulin (IVIg) treatment. Journal of Neurology, 2006, 253, v18-v24.	1.8	48
242	Remyelination strategies: New advancements toward a regenerative treatment in multiple sclerosis. Current Neurology and Neuroscience Reports, 2006, 6, 229-235.	2.0	8
243	Effects of interferon-beta on oligodendroglial cells. Journal of Neuroimmunology, 2006, 177, 173-180.	1.1	30
244	Oligodendrocyte precursor cells express a functional chemokine receptor CCR3: Implications for myelination. Journal of Neuroimmunology, 2006, 178, 17-23.	1.1	20
245	Does natalizumab have a role in the treatment of relapsing multiple sclerosis?. Nature Clinical Practice Neurology, 2006, 2, 476-477.	2.7	0
246	Remyelinating and neuroprotective treatments in multiple sclerosis. Expert Opinion on Investigational Drugs, 2004, 13, 331-347.	1.9	17
247	Guillain-Barri $\frac{1}{2}$ -Syndrom (akute entzi $\frac{1}{2}$ ndliche demyelinisierende Polyradikuloneuritis). Intensivmedizin Und Notfallmedizin, 2003, 40, 100-110.	0.2	0
248	Side effects of intravenous immunoglobulins in neurological autoimmune disorders. Journal of Neurology, 2003, 250, 818-821.	1.8	86
249	Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: implications for remyelination. Journal of Neuroimmunology, 2003, 138, 25-30.	1.1	19
250	Rat oligodendroglial cell lines express a functional receptor for the chemokine CCL3 (macrophage) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.0	0
251	Rat oligodendroglial cell lines express a functional receptor for the chemokine CCL3 (macrophage) Tj ETQq1 1 0.784314 rgBT/Overlock 12	1.0	12
252	Comparison of Intravenous Immunoglobulin Preparations on Microglial Function In Vitro: More Potent Immunomodulatory Capacity of an IgM/IgA-Enriched Preparation. Clinical Neuropharmacology, 2002, 25, 254-259.	0.2	17

#	ARTICLE	IF	CITATIONS
253	Remyelinating strategies for the treatment of multiple sclerosis. <i>Progress in Neurobiology</i> , 2002, 68, 361-376.	2.8	121
254	Remission of a CNS inflammatory disease accompanied by newly developed ANA and arthropathy during treatment with IFN-*. <i>Journal of Neurology</i> , 2002, 249, 1121-1122.	1.8	2
255	Oxides and apoptosis in inflammatory myopathies. <i>Microscopy Research and Technique</i> , 2001, 55, 249-258.	1.2	14
256	Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. <i>Developmental Brain Research</i> , 2001, 128, 77-81.	2.1	84
257	Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. <i>Journal of Neuroimmunology</i> , 2001, 112, 63-71.	1.1	46
258	Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (IVIg). <i>Journal of Neuroimmunology</i> , 2000, 103, 195-201.	1.1	47
259	Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes. <i>Journal of Neuroimmunology</i> , 1999, 96, 228-233.	1.1	31
260	Presentation and Prognosis of Bilateral Infarcts in the Territory of the Superior Cerebellar Artery. <i>Cerebrovascular Diseases</i> , 1999, 9, 328-333.	0.8	16
261	Mechanisms of High-Dose Intravenous Immunoglobulins in Demyelinating Diseases. <i>Archives of Neurology</i> , 1999, 56, 661.	4.9	71
262	Intravenous immunoglobulin treatment of neurological autoimmune diseases. <i>Journal of the Neurological Sciences</i> , 1998, 153, 203-214.	0.3	94
263	Side Effects of High-Dose Intravenous Immunoglobulins. <i>Clinical Neuropharmacology</i> , 1997, 20, 385-393.	0.2	77
264	Apoptosis of Myelin-Reactive T Cells Induced by Reactive Oxygen and Nitrogen Intermediates in Vitro. <i>Cellular Immunology</i> , 1997, 178, 1-8.	1.4	79
265	H2O2 and Nitric Oxide-mediated Oxidative Stress Induce Apoptosis in Rat Skeletal Muscle Myoblasts. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 36-43.	0.9	98
266	Sequence and diversity of rat T-cell receptor Tcra V8 gene segments. <i>Immunogenetics</i> , 1995, 42, 304-5.	1.2	1
267	Structural analysis of the rat T-cell receptor Tcra V4 gene family. <i>Immunogenetics</i> , 1995, 41, 125-30.	1.2	4
268	Transferrin receptor internalization sequence YXRF implicates a tight turn as the structural recognition motif for endocytosis. <i>Cell</i> , 1990, 63, 1061-1072.	13.5	525
269	Remyelinating and neuroprotective treatments in multiple sclerosis. , 0, .		1
270	Therapie der multiplen Sklerose: MedikamentÄrse AnsÄtze zur Remyelinisierung in PrÄrÄfung. , 0, , .		0